Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick N Harter

Showing results (171-180 of 205) with videos related to

Pageof 21
Sort By:
Oncotarget|March 10, 2016
Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomasLukas Jennewein, Michael W Ronellenfitsch, Patrick Antonietti, et al.
The Lancet. Oncology|November 3, 2023
A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groupsPhilipp Karschnia, Marion Smits, Guido Reifenberger, et al.
Brain Pathology (Zurich, Switzerland)|December 4, 2018
Distribution and prognostic impact of microglia/macrophage subpopulations in gliomasPia S Zeiner, Corinna Preusse, Anna Golebiewska, et al.
Acta Neuropathologica|March 23, 2021
TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymomaChristian Thomas, Felix Thierfelder, Malte Träger, et al.
The Journal of Clinical Investigation|February 5, 2020
Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumorsMichael W Ronellenfitsch, Patrick N Harter, Martina Kirchner, et al.
Nature Cancer|June 6, 2025
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumorsDongsheng Yuan, Robin Jugas, Petra Pokorna, et al.
Cancer Immunology Research|October 11, 2019
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGFMariangela Di Tacchio, Jadranka Macas, Jakob Weissenberger, et al.
Neurology|March 17, 2026
Clinical Manifestations of Primary CNS T-Cell Lymphoma: A Retrospective Study of Histopathologic, Molecular, and Neuroimaging FeaturesKatharina Johanna Müller, Philipp Karschnia, Leon D Kaulen, et al.
Cancer Research|February 6, 2019
Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in GlioblastomaGiorgia Mastrella, Mengzhuo Hou, Min Li, et al.
Acta Neuropathologica|August 11, 2020
Infratentorial IDH-mutant astrocytoma is a distinct subtypeRouzbeh Banan, Damian Stichel, Anja Bleck, et al.
Pageof 21

Showing results (171-180 of 205) with videos related to

Sort By:
Pageof 21
Oncotarget|March 10, 2016
Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomasLukas Jennewein, Michael W Ronellenfitsch, Patrick Antonietti, et al.
The Lancet. Oncology|November 3, 2023
A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groupsPhilipp Karschnia, Marion Smits, Guido Reifenberger, et al.
Brain Pathology (Zurich, Switzerland)|December 4, 2018
Distribution and prognostic impact of microglia/macrophage subpopulations in gliomasPia S Zeiner, Corinna Preusse, Anna Golebiewska, et al.
Acta Neuropathologica|March 23, 2021
TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymomaChristian Thomas, Felix Thierfelder, Malte Träger, et al.
The Journal of Clinical Investigation|February 5, 2020
Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumorsMichael W Ronellenfitsch, Patrick N Harter, Martina Kirchner, et al.
Nature Cancer|June 6, 2025
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumorsDongsheng Yuan, Robin Jugas, Petra Pokorna, et al.
Cancer Immunology Research|October 11, 2019
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGFMariangela Di Tacchio, Jadranka Macas, Jakob Weissenberger, et al.
Neurology|March 17, 2026
Clinical Manifestations of Primary CNS T-Cell Lymphoma: A Retrospective Study of Histopathologic, Molecular, and Neuroimaging FeaturesKatharina Johanna Müller, Philipp Karschnia, Leon D Kaulen, et al.
Cancer Research|February 6, 2019
Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in GlioblastomaGiorgia Mastrella, Mengzhuo Hou, Min Li, et al.
Acta Neuropathologica|August 11, 2020
Infratentorial IDH-mutant astrocytoma is a distinct subtypeRouzbeh Banan, Damian Stichel, Anja Bleck, et al.
Pageof 21